Most gout patients not controlled with allopurinol
Three-quarters of patients with gout will not have their urate levels controlled by allopurinol, reports a Dutch study.
The researchers said these patients would have to be switched to a second treatment – although the most effective second-line option is not available in the UK.
In the study, 82 patients with gout received 300mg allopurinol for two months. But only 24% reached a target urate of 300[micro]g/l, while 11% stopped taking the drug due to adverse events.
The authors say: 'It seems that benzbromarone is a highly efficacious oral urate-lowering drug, which has been excessively withdrawn from the market. Reintroduction of benzbromarone in the market might be preferred instead of using new costly drugs, carrying a risk for unknown adverse drug reactions.
'Treatment of gout might be more successful with better – restricted - availability of benzbromarone.'
Annals of the Rheumatic Diseases 6 February early online publication